LumiraDx Investor Presentation Deck

LumiraDx Today: Transforming Community-based Healthcare Next Generation POC(1) Diagnostic Company Large Installed Base with Global Commercial Reach Manufacturing Designed for Scale Broad Menu and Pipeline of Diagnostic Tests Experienced Management Team lumiraDx™ Addressing the current limitations of legacy POC systems by bringing lab-comparable performance to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership 25,000 instruments shipped to 105 countries across primary care, pharmacy, hospital emergency departments, global health, and other settings All current and future POC tests are developed on common strip design, enabling flexible, automated and low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID).(2) 50+ assays in three-year roadmap Fourth POC company for founding team. Management team has a successful track record of diagnostic innovation and building / scaling companies in POC (1) "POC" means point of care. (2) Global Total Addressable Market ("TAM"): We estimate each test based on our current assumptions, including (a) the existing marketsizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. Copyright ©2022 Lumirax Ltd. All Rights Reserved. Worldwide

View entire presentation